Research Progress on the Correlation between Metabolic Syndrome and Benign Prostatic Hyperplasia
Abstract
Metabolic syndrome is a group of clinical manifestations of metabolic abnormalities, which is closely related to the occurrence of various diseases and has become an important field in modern medical research. With the change of lifestyle, the incidence of metabolic syndrome has been increasing year by year. Research shows that its components, including obesity, insulin resistance, hypertension and dyslipidemia, may have a potential correlation with benign prostatic hyperplasia (BPH). Benign prostatic hyperplasia is a common male urinary system disease, and its occurrence mechanism is complex, involving multiple endocrine and metabolic pathways. Existing research has gradually revealed the role of the components of metabolic syndrome in the development of prostate hyperplasia, especially in aspects such as inflammatory response, changes in hormone levels and cell proliferation. However, although there have been preliminary research results, the specific mechanism between metabolic syndrome and prostate hyperplasia still needs to be further explored. Therefore, this review aims to systematically analyze the relationship between metabolic syndrome and its components and prostate hyperplasia, summarize the relevant mechanisms, and summarize the current research progress and future research directions, in order to provide a reference for clinical prevention and treatment.
References
[1]Alberti K.G., Zimmet P.Z.. (1998). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 15, 539–553.
[2] Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/
National Heart, Lung, and Blood Institute Scientific Statement [published correction appears in Circulation. 2005 Oct 25;112(17):e297] [pub-
lished correction appears in Circulation. 2005 Oct 25;112(17):e298]. Circulation. 2005;112(17):2735-2752.
[3] Wang YB, Yang L, Deng YQ, et al. Causal relationship between obesity, lifestyle factors and risk of benign prostatic hyperplasia: a
univariable and multivariable Mendelian randomization study. J Transl Med. 2022;20(1):495. Published 2022 Oct 29.
[4] Negi SK, Desai S, Faujdar G, et al. The correlation between obesity and prostate volume in patients with benign prostatic hyperplasia: A prospective cohort study. Urologia. 2024;91(3):512-517.
[5] Fan G, Guan X, Guan B, et al. Untargeted metabolomics reveals that declined PE and PC in obesity may be associated with prostate
hyperplasia. PLoS One. 2024;19(4):e0301011. Published 2024 Apr 19.
[6] Wang HH, Hsieh CJ, Lin KJ, et al. Waist circumference is an independent risk factor for prostatic hyperplasia in Taiwanese males.
Asian J Surg. 2011;34(4):163-167.
[7] Lee S, Min HG, Choi SH, et al. Central obesity as a risk factor for prostatic hyperplasia. Obesity (Silver Spring). 2006;14(1):172-179.
[8] Zhou B, Wang P, Xu WJ, et al. Correlations of glucose metabolism, insulin resistance and inflammatory factors with symptom score
of patients with benign prostatic hyperplasia. Eur Rev Med Pharmacol Sci. 2018;22(16):5077-5081.
[9] Ribeiro DL, Pinto ME, Maeda SY, Taboga SR, Góes RM. High fat-induced obesity associated with insulin-resistance increases
FGF-2 content and causes stromal hyperplasia in rat ventral prostate. Cell Tissue Res. 2012;349(2):577-588.
[10] Ozcan L, Besiroglu H, Dursun M, Polat EC, Otunctemur A, Ozbek E. Comparison of the clinical parameters of benign prostate
hyperplasia in diabetic and non diabetic patients. Arch Ital Urol Androl. 2017;89(1):26-30. Published 2017 Mar 31.
[11] Mubenga LE, Gruson D, Hermans MP, Bwenge E, Tombal B. Metabolic syndrome components and prostatic hyperplasia
among diabetic and non-diabetic men in the Eastern DR Congo: A cross-sectional study. Diabetes Metab Syndr. 2019;13(1):776-780.
[12] Xin C, Fan H, Xie J, Hu J, Sun X, Liu Q. Impact of Diabetes Mellitus on Lower Urinary Tract Symptoms in Benign Prostatic Hyperplasia Patients: A Meta-Analysis. Front Endocrinol (Lausanne). 2022;12:741748. Published 2022 Feb 1.
[13]Suzuki Y, Kaneko H, Okada A, et al. Benign Prostatic Hyperplasia and Incident Cardiovascular Disease. Circ J. 2024;88(3):408-416.
[14] Fu Y, Zhou Z, Yang B, Zhang K, He L, Zhang X. The Relationship between the Clinical Progression of Benign Prostatic Hyperplasia and Metabolic Syndrome: A Prospective Study. Urol Int. 2016;97(3):330-335.
[15] Sugaya K, Kadekawa K, Ikehara A, et al. Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia. Int J Urol. 2003;10(11):569-575.
[16] Güven EO, Selvi I, Karaismailoğlu E. Association between benign prostate enlargement-related storage and voiding symptoms
and systolic blood pressure: a single-center cross-sectional study. Sao Paulo Med J. 2019;137(5):446-453.
[17] Zeng XT, Weng H, Xiong J, et al. Comparison of Clinical and Physiological Parameters for Benign Prostatic Hyperplasia in Hypertensive and Normotensive Patients. Front Physiol. 2018;9:1330. Published 2018 Sep 24.
[18] Zhu C, Wu J, Wu Y, et al. Triglyceride to high-density lipoprotein cholesterol ratio and total cholesterol to high-density lipoprotein
cholesterol ratio and risk of benign prostatic hyperplasia in Chinese male subjects. Front Nutr. 2022;9:999995. Published 2022 Oct 3.
[19] Shih HJ, Huang CJ, Lin JA, Kao MC, Fan YC, Tsai PS. Hyperlipidemia is associated with an increased risk of clinical benign
prostatic hyperplasia. Prostate. 2018;78(2):113-120.
[20] Shen W, Yao HQ, Deng ZX, Zhang XM, Zhang LC, Hu WL. Zhonghua Nan Ke Xue. 2010;16(1):29-33.
[21] Zhang X, Zeng X, Dong L, Zhao X, Qu X. The effects of statins on benign prostatic hyperplasia in elderly patients with metabolic
syndrome. World J Urol. 2015;33(12):2071-2077.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.
